Current Report Filing (8-k)
June 14 2017 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 14, 2017
ALDEYRA THERAPEUTICS, INC.
(Exact name of Registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
|
|
001-36332
|
|
20-1968197
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
131 Hartwell Avenue, Suite 320
Lexington, MA 02421
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (781) 761-4904
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 7.01.
|
Regulation FD Disclosure.
|
On June 14, 2017, management of Aldeyra Therapeutics, Inc.
(Aldeyra) will hold a conference call at 8:00 am ET to discuss data from its randomized, dose-ranging, parallel-group, double-masked, vehicle-controlled, conjunctival allergen challenge Phase 2b clinical trial of 0.1% and 0.5% ADX-102
ophthalmic solution. A copy of the presentation being used in connection with this conference call is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, or incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
On June 14, 2017, Aldeyra issued a press release announcing data from its
randomized, dose-ranging, parallel-group, double-masked, vehicle-controlled, conjunctival allergen challenge Phase 2b clinical trial of 0.1% and 0.5% ADX-102 ophthalmic solution. A copy of Aldeyra press release is attached hereto as Exhibit
99.2 and is incorporated by reference herein.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Aldeyra Therapeutics, Inc. Presentation dated June 14, 2017
|
|
|
99.2
|
|
Aldeyra Therapeutics, Inc. Press Release dated June 14, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
ALDEYRA THERAPEUTICS, INC.
|
|
|
By:
|
|
/s/ Todd C. Brady, M.D., Ph.D.
|
|
|
Name:
|
|
Todd C. Brady, M.D., Ph.D.
|
|
|
Title:
|
|
President and Chief Executive Officer
|
Dated: June 14, 2017
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2024 to May 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From May 2023 to May 2024